The innate immune system houses cellular signaling proteins called pattern recognition receptors (PRRs) that are responsible for recognizing highly-conserved molecular patterns associated with pathogens or damage to elicit an immune response. However, NLRX1 is a unique PRR in the NOD-like receptor (NLR) family that instead functions to attenuate pro-inflammatory pathways that are activated by other PRRs, such as NF-κB and type-1 interferon signaling which both have implications in cancer. NLRX1 can regulate additional cancer-associated pathways, such as MAPK and AKT, and cancer-associated functions like metabolism and reactive oxygen species (ROS) production. Interestingly, depending on the type and subtype of cancer, NLRX1 can either be tumor promoting or tumor suppressing. Here, we investigate the role of NLRX1 in two deadly cancers: triple-negative breast cancer (TNBC) and pancreatic cancer. In a murine mammary tumor model that highly mimics TNBC, we discovered that NLRX1 is protective against disease burden in vivo when NLRX1 is expressed in healthy host cells. NLRX1 exerts its protection through limiting the recruitment of eosinophils to the tumor, suppressing epithelial-mesenchymal transition (EMT), and attenuating the formation of the metastatic niche. Conversely, when NLRX1 is instead expressed by the mammary tumor cells, NLRX1 promotes cancer-associated characteristics in vitro and disease burden in vivo by promoting EMT. This indicates that the role of NLRX1 in TNBC is highly dependent on cellular context. Conversely, in murine pancreatic cancer cells, we found that NLRX1 expression by the tumor cells is protective against cancer-associated characteristics in vitro, and that this is likely driven by NF-κB, MAPK, AKT, and inflammasome signaling with a potential to also limit immune evasion. Together, this research indicates that the role of NLRX1 can be highly variable based on the cell and tumor type and identifies the underlying mechanisms through which NLRX1 functions in these two cancer models. This is critical information for drug development initiatives so therapies can be developed that target NLRX1 in the appropriate cell type and in the appropriate disease. / Doctor of Philosophy / Inflammation, which is characterized by redness, heat, pain, swelling, and sometimes loss of function, is a critical way in which our bodies fight infections and repair tissue damage. However, chronic inflammation occurs when our bodies are unable to turn inflammation off and can result in cancerous mutations. Therefore, the successful resolution of inflammation is critical to maintaining inflammatory balance and has previously been dubbed the "Goldilocks Conundrum". The immune system houses a class of cellular signaling proteins called pattern recognition receptors (PRRs), which often function to turn inflammation on. However, a unique PRR in the NOD-like receptor (NLR) family called "NLRX1" functions to turn inflammation off and therefore plays an important role in preventing damaging chronic inflammation. NLRX1 has historically been studied in the context of infectious diseases, but because NLRX1 is involved in inflammation and because inflammation is a critical factor of cancer, its role as a tumor suppressor or tumor promoter has recently become an area of interest. NLRX1 has also been found to regulate biological pathways beyond inflammation that are also important for cancer initiation and progression. Interestingly, depending on the type and subtype of cancer, NLRX1 can either be tumor promoting or tumor suppressing. Here, we investigate the role of NLRX1 in two deadly cancers: triple-negative breast cancer (TNBC) and pancreatic cancer. In a mouse mammary tumor model that highly mimics TNBC, we discovered that NLRX1 is protective against disease burden when NLRX1 is expressed in healthy, non-tumor cells. NLRX1 exerts its protection through impacting the immune cells recruited to the tumor, limiting the ability of the tumor cells to leave the original tumor and spread throughout the body in the process known as metastasis, and suppressing the formation of a favorable tumor metastasis environment in the lung. Conversely, when NLRX1 is instead expressed by the mammary tumor cells, NLRX1 promotes disease burden by helping tumor cells leave the original tumor and spread throughout the body. This indicates that the role of NLRX1 in TNBC is highly dependent on cellular context, including if the cell is healthy or cancerous. Conversely, in mouse pancreatic cancer cells, we found that NLRX1 expression by the tumor cells is protective against cancer-associated characteristics. Together, this research indicates that the role of NLRX1 can be highly variable based on the cell and tumor type. This is critical information for drug development initiatives so therapies can be developed that turn NLRX1 on or off in the appropriate cell type and in the appropriate disease.

Nos últimos anos, inúmeros avanços têm sido alcançados no que diz respeito aos mecanismos moleculares que participam na indução e manutenção da dor crônica, incluindo ativação glial. Já foi demonstrado que alguns receptores de reconhecimento padrão (PRRs), como os receptores do tipo Toll (TLRs) participam desse processo e, que em modelos de inflamação/infecção do Sistema Nervoso Central, os TLRs e os receptores do tipo NOD (NLRs) cooperam na ativação das células da glia, o que nos levou a hipotetizar que os receptores NOD1 e NOD2 também possam desempenhar um papel importante no processo de dor crônica. O NOD2 é responsável pela detecção intracelular do muramil dipeptídeo (MDP) enquanto que NOD1 reconhece o ácido diaminopimélico (iE-DAP), ambos padrões moleculares associados a patógenos (PAMPs) encontrados no peptideoglicano de bactérias. Após o reconhecimento, NLRs recrutam diretamente RIPK2 (proteína 2 de interação com o receptor RICK), uma serina-treonina quinase importante na ativação do fator nuclear kB (NF-kB). Assim, o objetivo do presente estudo foi avaliar a participação de NOD1 e NOD2, via RIPK2, no desenvolvimento da hipersensibilidade mecânica neuropática focando principalmente nos mecanismos espinais envolvidos. Dessa maneira, foi observado que os animais NOD1-/-, NOD2-/- e RIPK2-/- apresentaram redução significativa da hipersensibilidade nociceptiva mecânica quando comparado aos animais selvagens após indução de neuropatia periférica pelo modelo experimental de lesão limitada do nervo isquiático (SNI, Spared Nerve Injury). Ao contrário, a hipersensibilidade inflamatória induzida pelo adjuvante completo de Freud (CFA) não foi reduzida nesses animais. A redução da dor neuropática em NOD1-/-, NOD2-/- e RIPK2-/- foi associada a uma diminuição da expressão de IBA-1, GFAP, IL-1, TNF- e P2X4 na medula espinal quando comparado ao grupo WT. In vitro, foi observado que culturas primárias de micróglia não induziram liberação de IL-1, TNF-, IL-6 em resposta ao MDP (10g/mL) e iE-DAP (100ng/mL). No entanto, quando o MDP foi administrado juntamente com uma baixa concentração de lipopolissacarídeo (LPS) (0,1ng/mL), apresentou uma forte produção destas citocinas. Além disso, também foi demonstrado que células periféricas que infiltram na medula espinal podem expressar NOD1 e NOD2 e portanto serem capazes de induzir hipersensibilidade mecânica e ativação microglial após a indução de neuropatia. Dessa maneira, os resultados sugerem que NOD1 e NOD2, via RIPK2, contribuem para a gênese da dor neuropática, possivelmente mediando a liberação de citocinas pró-nociceptivas e a ativação de células gliais. Além disso, os resultados apontam ação potencial de NOD2 com TLR4 no intuito de estimular a ativação glial. Estes mecanismos representam uma nova abordagem para elucidar os mecanismos envolvidos na fisiopatologia da dor crônica e um possível alvo para o desenvolvimento de drogas para o tratamento da dor neuropática. / In the last years, many advances have been made related to the molecular mechanisms involved in the induction and maintenance of chronic pain, including glial activation. It has been shown that some pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) are involved in this process, and that in inflammation/infection models of the CNS, the TLRs and Nod-like receptors (NLRs) cooperate in activation of glial cells, which led us to hypothesize that NOD1 and NOD2 receptors may also play an important role in chronic pain process. NOD2 are responsible by intracellular detection of muramyl dipeptide (MDP) and NOD1 detects meso-diaminopimelic acid (iE-DAP), pathogen-associated molecular patterns (PAMPs) found in the peptidoglycan from bacteria. Upon recognition, NLRs recruit directly RIPK2, an adaptor protein, important in NLRs-mediated NFB activation. In the present study, we aimed to evaluate the participation of NOD1 and NOD2, via RIPK2, in the development of neuropathic mechanical hypersensitivity focusing mainly on spinal mechanisms involved. The results demonstrate that NOD1-/-, NOD2-/-, RIPK2-/- showed a significant reduction in mechanical hypersensitivity when compared to WT mice, after submitted to an experimental model of neuropathic pain Spared Nerve Injury (SNI). Interestingly, CFA-induced chronic inflammatory hypersensitivity was not decreased in these mice. The reduction in neuropathic pain in NOD1-/-, NOD2-/- and RIPK2-/- mice was associated with a decrease in the expression of IBA-1, GFAP, IL-1, TNF- and P2X4 in spinal cord when compared with WT. In vitro, it was observed that primary cultures of microglia did not produce IL-1, TNF-, IL-6 in response to MDP (3g/mL) or iE-DAP (100ng/mL). However, MDP, together with an ineffective concentration of LPS (0.1ng/mL), produced a robust production of these cytokines. Moreover, it was also demonstrated that peripheral cells infiltrating the spinal cord could express NOD1 and NOD2 and thus, be able to induce mechanical hypersensitivity and microglial activation after induction of peripheral neuropathy. The results suggest that NOD1 and NOD2, via RIPK2, contribute to the genesis of neuropathic pain, possibly by mediating the release of pronociceptive cytokines and increased glial cells activation. Moreover, the results indicate potential action of NOD2 with TLR4 in attempt to stimulate glial cells activation. These mechanisms represent a novel approach for elucidating the pathophysiology of chronic pain, and a target for the development of drugs for the treatment of neuropathic pain.

Nos últimos anos, inúmeros avanços têm sido alcançados no que diz respeito aos mecanismos moleculares que participam na indução e manutenção da dor crônica, incluindo ativação glial. Já foi demonstrado que alguns receptores de reconhecimento padrão (PRRs), como os receptores do tipo Toll (TLRs) participam desse processo e, que em modelos de inflamação/infecção do Sistema Nervoso Central, os TLRs e os receptores do tipo NOD (NLRs) cooperam na ativação das células da glia, o que nos levou a hipotetizar que os receptores NOD1 e NOD2 também possam desempenhar um papel importante no processo de dor crônica. O NOD2 é responsável pela detecção intracelular do muramil dipeptídeo (MDP) enquanto que NOD1 reconhece o ácido diaminopimélico (iE-DAP), ambos padrões moleculares associados a patógenos (PAMPs) encontrados no peptideoglicano de bactérias. Após o reconhecimento, NLRs recrutam diretamente RIPK2 (proteína 2 de interação com o receptor RICK), uma serina-treonina quinase importante na ativação do fator nuclear kB (NF-kB). Assim, o objetivo do presente estudo foi avaliar a participação de NOD1 e NOD2, via RIPK2, no desenvolvimento da hipersensibilidade mecânica neuropática focando principalmente nos mecanismos espinais envolvidos. Dessa maneira, foi observado que os animais NOD1-/-, NOD2-/- e RIPK2-/- apresentaram redução significativa da hipersensibilidade nociceptiva mecânica quando comparado aos animais selvagens após indução de neuropatia periférica pelo modelo experimental de lesão limitada do nervo isquiático (SNI, Spared Nerve Injury). Ao contrário, a hipersensibilidade inflamatória induzida pelo adjuvante completo de Freud (CFA) não foi reduzida nesses animais. A redução da dor neuropática em NOD1-/-, NOD2-/- e RIPK2-/- foi associada a uma diminuição da expressão de IBA-1, GFAP, IL-1, TNF- e P2X4 na medula espinal quando comparado ao grupo WT. In vitro, foi observado que culturas primárias de micróglia não induziram liberação de IL-1, TNF-, IL-6 em resposta ao MDP (10g/mL) e iE-DAP (100ng/mL). No entanto, quando o MDP foi administrado juntamente com uma baixa concentração de lipopolissacarídeo (LPS) (0,1ng/mL), apresentou uma forte produção destas citocinas. Além disso, também foi demonstrado que células periféricas que infiltram na medula espinal podem expressar NOD1 e NOD2 e portanto serem capazes de induzir hipersensibilidade mecânica e ativação microglial após a indução de neuropatia. Dessa maneira, os resultados sugerem que NOD1 e NOD2, via RIPK2, contribuem para a gênese da dor neuropática, possivelmente mediando a liberação de citocinas pró-nociceptivas e a ativação de células gliais. Além disso, os resultados apontam ação potencial de NOD2 com TLR4 no intuito de estimular a ativação glial. Estes mecanismos representam uma nova abordagem para elucidar os mecanismos envolvidos na fisiopatologia da dor crônica e um possível alvo para o desenvolvimento de drogas para o tratamento da dor neuropática. / In the last years, many advances have been made related to the molecular mechanisms involved in the induction and maintenance of chronic pain, including glial activation. It has been shown that some pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) are involved in this process, and that in inflammation/infection models of the CNS, the TLRs and Nod-like receptors (NLRs) cooperate in activation of glial cells, which led us to hypothesize that NOD1 and NOD2 receptors may also play an important role in chronic pain process. NOD2 are responsible by intracellular detection of muramyl dipeptide (MDP) and NOD1 detects meso-diaminopimelic acid (iE-DAP), pathogen-associated molecular patterns (PAMPs) found in the peptidoglycan from bacteria. Upon recognition, NLRs recruit directly RIPK2, an adaptor protein, important in NLRs-mediated NFB activation. In the present study, we aimed to evaluate the participation of NOD1 and NOD2, via RIPK2, in the development of neuropathic mechanical hypersensitivity focusing mainly on spinal mechanisms involved. The results demonstrate that NOD1-/-, NOD2-/-, RIPK2-/- showed a significant reduction in mechanical hypersensitivity when compared to WT mice, after submitted to an experimental model of neuropathic pain Spared Nerve Injury (SNI). Interestingly, CFA-induced chronic inflammatory hypersensitivity was not decreased in these mice. The reduction in neuropathic pain in NOD1-/-, NOD2-/- and RIPK2-/- mice was associated with a decrease in the expression of IBA-1, GFAP, IL-1, TNF- and P2X4 in spinal cord when compared with WT. In vitro, it was observed that primary cultures of microglia did not produce IL-1, TNF-, IL-6 in response to MDP (3g/mL) or iE-DAP (100ng/mL). However, MDP, together with an ineffective concentration of LPS (0.1ng/mL), produced a robust production of these cytokines. Moreover, it was also demonstrated that peripheral cells infiltrating the spinal cord could express NOD1 and NOD2 and thus, be able to induce mechanical hypersensitivity and microglial activation after induction of peripheral neuropathy. The results suggest that NOD1 and NOD2, via RIPK2, contribute to the genesis of neuropathic pain, possibly by mediating the release of pronociceptive cytokines and increased glial cells activation. Moreover, the results indicate potential action of NOD2 with TLR4 in attempt to stimulate glial cells activation. These mechanisms represent a novel approach for elucidating the pathophysiology of chronic pain, and a target for the development of drugs for the treatment of neuropathic pain.

Un des enjeux majeurs de la thérapie contre le cancer est le développement d’immunothérapies innovantes ciblées et efficaces sur le long terme. Dans ce but, nous avons tiré profit de la versatilité des liposomes pour concevoir une plateforme vaccinale modulable associant i) un épitope peptidique CD4 universel capable de stimuler les lymphocytes T CD4+, ii) un épitope peptidique CD8 dérivé de la tumeur, induisant la différenciation des lymphocytes T CD8+ en lymphocytes T cytotoxiques et iii) un ou des agonistes des récepteurs Toll-like ou NOD-like qui agissent comme des adjuvants en activant les cellules dendritiques. Après plusieurs étapes de criblage, trois vaccins ont été développés, spécifiques d’un modèle orthotopique de cancer du poumon (TC-1) et différant uniquement par leur adjuvant. Une étude comparative dans un modèle murin a été réalisée. Ces travaux ont permis de comparer leur limite temporelle d’efficacité, de mettre en évidence leur mécanismes immunitaires respectifs et de démontrer la supériorité thérapeutique des liposomes contenant un agoniste du TLR4 (MPLA). Ces travaux ont montré l’intérêt d’une plateforme liposomique modulable pour la conception de vaccins personnalisés. / Currently, a challenging goal in the area of cancer treatment is the development of innovative targeted antitumoral immunotherapies with a long-term efficiency. In this context, we took advantage of liposomal nanoparticles properties for the conception of a tunable vaccine platform allowing the strategical conception of vaccines containing: i) a CD4 epitope peptide able to stimulate CD4+ T helper cells ii) a tumor CD8 epitope peptide, which induces the differentiation of CD8+ T cells in cytotoxic T cells and iii) Toll or Nod-Like receptor agonist(s), which act as adjuvant for the activation of dendritic cell. After several screening steps, three vaccines, specific tardeting an orthotopic lung tumor model (TC-1) and differing only by their adjuvant composition, were successfully developed. Subsequently, a comparative study of their efficacy time limit and their immunologic mode of action was performed. This study showed the therapeutic supremacy of liposomal vaccines containing a TLR4 agonist (MPLA). In this work, we demonstrated the value of a customizable liposomal platform for the conception of personalized vaccines and we highlighted the necessity of immune monitoring for a better understanding of vaccines impact and the prediction of their efficacy.

Entre os PRRs (receptores de reconhecimento padrão), NOD-like receptors (NLRs), tal como NOD2, são responsáveis pela detecção intracelular de muramil dipeptídeo (MDP); padrão molecular associado a patógeno (PAMP), encontrado no peptidoglicano (PGN) de praticamente todas bactérias GRAM positiva e negativa. Após o reconhecimento e estimulação por MDP, NOD2 recruta diretamente a serina-treonina quinase RIPK2, uma proteína adaptadora importante na ativação de NF?B mediada por NOD2. A expressão de NOD2 foi descrita em macrófagos e em outras células. Além disso, trabalhos anteriores indicaram que PRRs desempenham papel crucial na ativação de células gliais da medula espinal, na indução e manutenção da dor inflamatória crônica e dor neuropática. No presente estudo, avaliamos o papel de NOD2 na modulação da sensibilidade à dor, focando sua importância na ativação de células da glia da medula espinal, bem como a sua via de sinalização (RIPK2) e liberação de citocinas pró-nociceptivas, como o fator de necrose tumoral alfa (TNF-?), interleucina-6 (IL-6) e interleucina-1 beta (IL-1?). Os resultados demonstram que camundongos selvagens tratados com MDP, apresentaram diminuição no limiar nociceptivo mecânico (pico entre 3 e 5 horas) comparado com o grupo controle (veículo), retornando ao basal após 48 horas. Além disso, camundongos NOD2-/- , RIPK2-/- , TNFR1/2-/- e IL-6 -/- tratados com MDP não diferiram o limiar nociceptivo mecânico, comparado com seus respectivos grupos controle (veículo). Entretanto, camundongos TNFR1- /- , CCR2-/- , TLR4-/- , MyD88-/- e TRIF-/- tratados com MDP, apresentaram diminuição no limiar nociceptivo mecânico similar aos camundongos selvagens tratados com MDP. Adicionalmente, o pré-tratamento de camundongos selvagens com IL-1ra, propentofilina, minociclina, fluorocitrato e SB 203580 inibiu o desenvolvimento da hipersensibilidade mecânica induzida por MDP. Estes dados sugerem que a ativação do sensor intracellular NOD2 esta presente em células da glia da medula espinal e estimula a ativação das vias de sinalização RIPK2 e p38 MAPK com subsequente produção de IL-1?, IL-6 e TNF?, por uma via de sinalização independente de TLR4, MyD88 e TRIF. Finalmente, estes mecanismos contribuem para o processo de hipersensibilidade mecânica durante a neuropatia periférica e representam uma nova abordagem para elucidar os mecanismos envolvidos na fisiopatologia da dor crônica. / Among PRRs (pattern recognition receptors), NOD-like receptors (NLRs), such as NOD2 are responsible by intracellular detection of muramyl dipeptide (MDP); pathogen-associated molecular pattern (PAMP) found in the peptidoglycan (PGN) from virtually all gram positive and gram negative bacteria. Upon recognition and stimulation by MDP, NOD2 recruits directly the receptor-interacting serine/threonine-protein kinase 2 (RIPK2), an adaptor protein important in the NOD2-mediated NF?B activation. The expression of NOD2 has been described in macrophages and other cells. Moreover, previous work has indicated that PRRs play a crucial role in the activation of spinal cord glial cells, in the induction and maintenance of chronic inflammatory and neuropathic pain. In the present study, we aimed to evaluate the role of NOD2 in the modulation of pain sensitivity, focusing on its importance in the activation of spinal cord glial cells, as well as its signaling pathway (RIPK2) and release of pro-nociceptive cytokines, such as tumour necrosis factor-alpha (TNF-?), interleukin-6 (IL-6) and interleukin-1beta (IL-1?). The results demonstrate that WT mice treated with MDP showed a decrease in mechanical nociceptive threshold (peak 3 to 5 hours) compared with the control group (vehicle), returning to the base line after 48 hours. Furthermore, NOD2-/- , RIPK2-/- , TNFR1/2-/- and IL-6 -/- mice treated with MDP did not differ the mechanical nociceptive threshold compared with their respective control groups (vehicle). However, TNFR1-/- , CCR2-/- , TLR4-/- , MyD88-/- and TRIF-/- mice treated MDP, showed a decrease in mechanical nociceptive threshold similar to WT mice treated with MDP. In addition, the pretreatment of WT mice with IL-1ra, propentofylline, minocycline, fluorocitrate and SB 203580 inhibited the development of mechanical hypersensitivity induced by MDP. These data suggest that activation of the intracellular sensor NOD2 present in spinal cord glial cells stimulates the activation of RIPK2 and p38 MAPK signaling pathways and subsequent production of IL-1?, IL-6 and TNF?, in a TLR4-, MyD88- and TRIF-independent signaling pathway. Finally, these mechanisms contribute to the process of mechanical hypersensitivity during peripheral neuropathy and represent a novel approach for elucidating the mechanisms underlying pathophysiology of chronic pain.

Toll-like Rezeptoren (TLR) und Nod-like Rezeptoren (NLR) sind Muster-erkennende Rezeptoren des angeborenen Immunsystems, die bakterielle Zellwandbestandteile erkennen können. Interleukin (IL)-1beta ist ein streng reguliertes Zytokin. Durch eine erste Stimulation wird der TLR-Rezeptor ausgelöst und führt zur Expression des Vorläuferproteins proIL-1beta. Durch einen zweiten Stimulus wird ein zytoplasmatischer NLR-Rezeptor zur Caspase1-Aktivierung angeregt. Dies führt zur post-translationalen Reifung von proIL-1beta zu reifem IL-1beta und zur Aktivierung weiterer Mechanismen der Pathogen-Eliminierung während einer bakteriellen Meningitis. Im ersten Teil dieser Arbeit wurde die synergistische Beziehung zwischen TLRs und NOD2 in Bezug auf die IL-1beta-Sekretion in Astrozyten und Mikroglia untersucht. Primäre murine WT-Astrozyten und eine humane Zelllinie, die mit Lipopolysaccharid (LPS) oder Lipopeptid sowie Muramyldipeptid (MDP) stimuliert wurden, zeigten signfikant erhöhte IL-1beta-Werte. IL-1beta war in NOD2-/- Astrozyten nicht erhöht. NOD2 trägt demnach als MDP-ausgelöster Rezeptor in Astrozyten, vermutlich zusammen mit dem Inflammasom-Komplex, zur Caspase-1-Aktivierung bei. In Mikrogliazellen lässt sich der bei Astrozyten gezeigte Effekt nicht reproduzieren. Zum ersten Mal wurde gezeigt, dass die TLR-abhängige IL-1beta-Antwort durch NOD2-Beteiligung in murinen und humanen Astrozyten synergistisch erhöht wird. In einem weiteren Versuchsteil wurde in primären murinen Peritonealmakrophagen von adulten Mäusen der TLR/NLR-Synergismus untersucht. Es stellte sich überraschenderweise heraus, dass weibliche NOD2-/- Mäuse zu einer synergistisch erhöhten IL-1beta-Sekretion fähig waren. SiRNA-Versuche mit in Östrogen vorinkubierten RAW264.7-NOD2-/- Zellen zeigten eine eindeutige Synergie der TLR4- und NOD2-Rezeptoren in der IL-1beta-Ausschüttung. Östrogen scheint weiblichen Individuen einen protektiven Vorteil vor Infektionen bei NOD2-Defizienz zu verschaffen. / Toll-like receptors (TLR) and nod-like receptors (NLR) are pattern-recognition receptors that recognize lipopolysaccharide (LPS), lipopeptides and myramyldipeptide (MDP) derived from bacterial cell wall. We focus our question on the regulation of the pro-inflammatory cytokine interleukin (IL)-1beta during bacterial meningitis in primary murine astrocytes and microglia as well as cell lines and the synergism of TLR4 or TLR2 and NOD2 to amplify IL-1beta-expression. ProIL-1beta is expressed by TLR-stimulation and activation of NF-kB signal transduction. Through the activation of Caspase-1, possibly through NOD2 and the inflammasome, proIL-1beta is cleaved on post-translational level and obtains its activated status, leading to pathogen elimination during bacterial meningitis. Primary murine WT-astrocytes and a human cell line primed with LPS or lipopeptide and stimulated with MDP show significantly increased IL-1beta levels in the supernatant. NOD2-/- astrocytes do not show elevated IL-1beta levels. After screening of cytoplasmic proCaspase-1 and activated Caspase-1 by Western blot it became clear, that stimulation of NOD2 with MDP led to Caspase-1 activation and thus to IL-1beta maturation in primary murine WT-astrocytes. We demonstrate for the first time that the synergism between TLR4 and NOD2 leads to significantly elevated IL-1beta levels and that NOD2 is capable of activating caspase-1 in primary murine astrocytes. Another part of the work was to test the TLR/NLR-synergism on primary peritoneal macrophages from adult mice. Surprisingly, female NOD2-/- mice showed significantly elevated IL-1beta levels. SiRNA- and stimulation-experiments with RAW264.7-NOD2-/- cells pre-incubated in estrogen show a clear synergy in IL-1beta secretion through TLR4 and NOD2 receptors. Estrogen seems to protect females from infection when having a NOD2 deficiency.

Entre os PRRs (receptores de reconhecimento padrão), NOD-like receptors (NLRs), tal como NOD2, são responsáveis pela detecção intracelular de muramil dipeptídeo (MDP); padrão molecular associado a patógeno (PAMP), encontrado no peptidoglicano (PGN) de praticamente todas bactérias GRAM positiva e negativa. Após o reconhecimento e estimulação por MDP, NOD2 recruta diretamente a serina-treonina quinase RIPK2, uma proteína adaptadora importante na ativação de NF?B mediada por NOD2. A expressão de NOD2 foi descrita em macrófagos e em outras células. Além disso, trabalhos anteriores indicaram que PRRs desempenham papel crucial na ativação de células gliais da medula espinal, na indução e manutenção da dor inflamatória crônica e dor neuropática. No presente estudo, avaliamos o papel de NOD2 na modulação da sensibilidade à dor, focando sua importância na ativação de células da glia da medula espinal, bem como a sua via de sinalização (RIPK2) e liberação de citocinas pró-nociceptivas, como o fator de necrose tumoral alfa (TNF-?), interleucina-6 (IL-6) e interleucina-1 beta (IL-1?). Os resultados demonstram que camundongos selvagens tratados com MDP, apresentaram diminuição no limiar nociceptivo mecânico (pico entre 3 e 5 horas) comparado com o grupo controle (veículo), retornando ao basal após 48 horas. Além disso, camundongos NOD2-/- , RIPK2-/- , TNFR1/2-/- e IL-6 -/- tratados com MDP não diferiram o limiar nociceptivo mecânico, comparado com seus respectivos grupos controle (veículo). Entretanto, camundongos TNFR1- /- , CCR2-/- , TLR4-/- , MyD88-/- e TRIF-/- tratados com MDP, apresentaram diminuição no limiar nociceptivo mecânico similar aos camundongos selvagens tratados com MDP. Adicionalmente, o pré-tratamento de camundongos selvagens com IL-1ra, propentofilina, minociclina, fluorocitrato e SB 203580 inibiu o desenvolvimento da hipersensibilidade mecânica induzida por MDP. Estes dados sugerem que a ativação do sensor intracellular NOD2 esta presente em células da glia da medula espinal e estimula a ativação das vias de sinalização RIPK2 e p38 MAPK com subsequente produção de IL-1?, IL-6 e TNF?, por uma via de sinalização independente de TLR4, MyD88 e TRIF. Finalmente, estes mecanismos contribuem para o processo de hipersensibilidade mecânica durante a neuropatia periférica e representam uma nova abordagem para elucidar os mecanismos envolvidos na fisiopatologia da dor crônica. / Among PRRs (pattern recognition receptors), NOD-like receptors (NLRs), such as NOD2 are responsible by intracellular detection of muramyl dipeptide (MDP); pathogen-associated molecular pattern (PAMP) found in the peptidoglycan (PGN) from virtually all gram positive and gram negative bacteria. Upon recognition and stimulation by MDP, NOD2 recruits directly the receptor-interacting serine/threonine-protein kinase 2 (RIPK2), an adaptor protein important in the NOD2-mediated NF?B activation. The expression of NOD2 has been described in macrophages and other cells. Moreover, previous work has indicated that PRRs play a crucial role in the activation of spinal cord glial cells, in the induction and maintenance of chronic inflammatory and neuropathic pain. In the present study, we aimed to evaluate the role of NOD2 in the modulation of pain sensitivity, focusing on its importance in the activation of spinal cord glial cells, as well as its signaling pathway (RIPK2) and release of pro-nociceptive cytokines, such as tumour necrosis factor-alpha (TNF-?), interleukin-6 (IL-6) and interleukin-1beta (IL-1?). The results demonstrate that WT mice treated with MDP showed a decrease in mechanical nociceptive threshold (peak 3 to 5 hours) compared with the control group (vehicle), returning to the base line after 48 hours. Furthermore, NOD2-/- , RIPK2-/- , TNFR1/2-/- and IL-6 -/- mice treated with MDP did not differ the mechanical nociceptive threshold compared with their respective control groups (vehicle). However, TNFR1-/- , CCR2-/- , TLR4-/- , MyD88-/- and TRIF-/- mice treated MDP, showed a decrease in mechanical nociceptive threshold similar to WT mice treated with MDP. In addition, the pretreatment of WT mice with IL-1ra, propentofylline, minocycline, fluorocitrate and SB 203580 inhibited the development of mechanical hypersensitivity induced by MDP. These data suggest that activation of the intracellular sensor NOD2 present in spinal cord glial cells stimulates the activation of RIPK2 and p38 MAPK signaling pathways and subsequent production of IL-1?, IL-6 and TNF?, in a TLR4-, MyD88- and TRIF-independent signaling pathway. Finally, these mechanisms contribute to the process of mechanical hypersensitivity during peripheral neuropathy and represent a novel approach for elucidating the mechanisms underlying pathophysiology of chronic pain.